Bio-Rad Laboratories and Oncocyte Collaborate to Launch GraftAssure

Oncocyte and Bio-Rad Laboratories have collaborated on the marketing of GraftAssure assay.  

While Oncocyte will spearhead the marketing, the two companies will collaborate for the commercialization of GraftAssure in Germany and the United States.  

Outside of Germany and the US, Bio-Rad has sole authority over GraftAssure’s production and marketing.  

The diagnostic is expected to hit the market later in 2024, but initially will be available to US-based educational transplant facilities.  

GraftAssure employs droplet digital polymerase chain reaction to measure cell-free DNA for the identification of graft damage.  

Josh Riggs, the head executive at Oncocyte, stated, “As we move towards launch, having the support of the Bio-Rad team in the US and Germany gives us the scale we need to meet the market opportunity.”  

Riggs went on to add, “The QX600 ddPCR platform, along with their expertise in serving the life science market, makes Bio-Rad a natural partner for our transplant technology.”   

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.